{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-015762","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2026-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.686538+00:00","generated_at":"2026-05-14T21:07:35.815267+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Moleculin Biotech secures Hong Kong patent for liposomal Annamycin through 2040","bullets":["Hong Kong patent No. 40073244 covers proprietary reconstitution method of liposomal Annamycin, expiring June 25, 2040.","Invention jointly owned with The University of Texas System; extends IP protection across four continents.","Company expects first Phase 3 clinical data release for Annamycin later this quarter.","Existing granted/allowed patents include US, Australia, Canada, China, Europe, India, Israel, Japan, Mexico, Singapore, Taiwan."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-015762","json":"https://secwatch.observer/filing/0001437749-26-015762.json","markdown":"https://secwatch.observer/filing/0001437749-26-015762.md","text":"https://secwatch.observer/filing/0001437749-26-015762.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926015762/0001437749-26-015762-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926015762/mbrx20260507_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:07:35.815267+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}